CNSP
CNS Pharmaceuticals, Inc.
Healthcare — Biotechnology
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Price History
Fundamentals
| Market Cap | $6.84M |
| P/E Ratio (TTM) | - |
| Forward P/E | -12.00 |
| EPS (TTM) | $-24.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -298.64% |
| Debt/Equity | 328.62 |
| Recommendation | None |
| Analyst Target | $10.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 51.4 |
| Beta | 1.03 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.39 |
| 52-Week Low | $1.90 |
| 50-Day Avg | $4.68 |
| 200-Day Avg | $5.51 |
| Avg Volume | $1.45M |
| Volume | 8.3K |
Performance Analysis
NEUTRALCNSP presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report